Persistence of antibodies 1 year after sequential administration of the 13-valent pneumococcal conjugate vaccine and the 23-valent pneumococcal polysaccharide vaccine in adults

• Main Authors: Beate Schmoele-Thoma (Author), Martin van Cleeff (Author), Richard N. Greenberg (Author), Alejandra Gurtman (Author), Thomas R. Jones (Author), Vani Sundaraiyer (Author), William C. Gruber (Author), Daniel A. Scott (Author)
• Format: Book
• Published: Taylor & Francis Group, 2019-03-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Vaccination with the 13-valent pneumococcal conjugate vaccine (PCV13) followed ≥ 1 year by the 23-valent pneumococcal polysaccharide vaccine (PPSV23) is recommended for immunocompetent adults ≥ 65 years of age in the United States. This study assessed antipneumococcal opsonophagocytic activity (OPA)...